The US has launched an initiative, referred to as Operation TrialBlazer, aimed at accelerating and modernizing clinical development. The effort appears to involve both the FDA and the Department of Health and Human Services, with the goal of restoring US leadership in clinical trials and biomedical innovation. However, there is some uncertainty about the specifics of the initiative, with varying descriptions of its scope and objectives.